Don B Sanders
Overview
Explore the profile of Don B Sanders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
973
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hayden H, Nelson M, Ross S, Verster A, Bouzek D, Eng A, et al.
Pediatr Pulmonol
. 2025 Mar;
60(3):e71024.
PMID: 40042126
Background: Systemic antibiotics can impact all microbes inhabiting patients, regardless of the intended target organism(s). We studied the simultaneous effects on respiratory and fecal microbiomes of β-lactam antibiotics administered for...
2.
Cromwell E, Ostrenga J, Sanders D, Morgan W, Castellani C, Szczesniak R, et al.
Eur Respir J
. 2024 Sep;
64(5).
PMID: 39227072
Background: Elexacaftor/tezacaftor/ivacaftor (ETI), which is approved for people with cystic fibrosis (pwCF) with a F508del variant, was further approved based on data in the USA for those carrying at least...
3.
Sanders D, Mayer-Hamblett N, Rosenfeld M, Polinieni D, Dasenbrook E, Szczesniak R, et al.
J Cyst Fibros
. 2024 Jul;
PMID: 39079877
Background: We characterized people with cystic fibrosis (CF) ineligible by genotype (not age) for currently approved CFTR modulator therapy using data from the US CF Foundation Patient Registry (CFFPR). Methods:...
4.
Burgel P, Southern K, Addy C, Battezzati A, Berry C, Bouchara J, et al.
J Cyst Fibros
. 2024 Jan;
23(2):187-202.
PMID: 38233247
This is the third in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on recognising...
5.
McElvaney O, Heltshe S, Odem-Davis K, West N, Sanders D, Fogarty B, et al.
Ann Am Thorac Soc
. 2023 Dec;
21(5):716-726.
PMID: 38096105
Pulmonary exacerbations (PEx) remain the most common cause of morbidity, recurrent hospitalization, and diminished survival in people with cystic fibrosis (PWCF) and are characterized by excess inflammation. Corticosteroids are potent,...
6.
Kopp B, Ross S, Bojja D, Guglani L, Chandler J, Tirouvanziam R, et al.
J Cyst Fibros
. 2023 Nov;
23(2):219-225.
PMID: 37977937
Background: Detecting airway inflammation non-invasively in infants with cystic fibrosis (CF) is difficult. We hypothesized that markers of inflammation in CF [IL-1β, IL-6, IL-8, IL-10, IL-17A, neutrophil elastase (NE) and...
7.
Thornton C, Caverly L, Kalikin L, Carmody L, McClellan S, LeBar W, et al.
Ann Am Thorac Soc
. 2023 Nov;
21(4):595-603.
PMID: 37963297
Rates of viral respiratory infection (VRI) are similar in people with cystic fibrosis (CF) and the general population; however, the associations between VRI and CF pulmonary exacerbations (PEx) require further...
8.
Gold L, Hansen R, Heltshe S, Flume P, Goss C, West N, et al.
J Cyst Fibros
. 2023 Oct;
23(2):278-281.
PMID: 37805355
Previous studies indicate that hospital rather than home treatment of pulmonary exacerbations (PEx) in people with cystic fibrosis (CF) can improve outcomes. We evaluated characteristics of adult participants from the...
9.
Sanders D, Bartz T, Zemanick E, Hoppe J, Stukovsky K, Cogen J, et al.
Ann Am Thorac Soc
. 2023 Sep;
20(12):1769-1776.
PMID: 37683122
Despite the high prevalence and clear morbidity of cystic fibrosis (CF) pulmonary exacerbations (PEx), there have been no published clinical trials of outpatient exacerbation management. To assess the feasibility of...
10.
McElvaney O, Heltshe S, Odem-Davis K, West N, Sanders D, Fogarty B, et al.
J Cyst Fibros
. 2023 Jul;
22(5):875-879.
PMID: 37407341
Background: Pulmonary exacerbations (PEx) remain a major cause of morbidity and mortality in people with cystic fibrosis (PWCF). Although the combination cystic fibrosis transmembrane conductance regulator (CFTR) modulators lumacaftor/ivacaftor and...